ASH

Videos

Real-World Treatment Patterns, FLT3 Testing, and Outcomes in AML

01/14/2021

Amer Zeidan, MBBS, MHS, discusses results from a retrospective study examining FLT3 testing trends, treatment patterns, and overall survival in relapsed/refractory AML.

Amer Zeidan, MBBS, MHS,...

01/14/2021

Journal of Clinical Pathways

Videos

Real-World Biomarker Testing, Treatment Patterns in CLL/SLL

12/17/2020

Anthony Mato, MD, discusses prognostic biomarker testing, treatment practices, and outcomes among patients with CLL in the clinical practice setting, using the informCLL prospective registry.

Anthony Mato, MD, discusses...

12/17/2020

Journal of Clinical Pathways

Conference Coverage

Real-World Toxicity and Tolerability of Ibrutinib for CLL or SLL

12/09/2020

Journal of Clinical Pathways

Conference Coverage

Comparison of HCRU and Costs Associated With Treatments for Relapsed/Refractory DLBCL

12/06/2020

HCRU and costs associated with CAR-T therapy were greater than transplantation for DLBCL and cost offsets before and after the procedures provide useful insight for treatment planning.

HCRU and costs associated with...

12/06/2020

Journal of Clinical Pathways

Conference Coverage

Enasidenib Effective for Relapsed/Refractory IDH2-Mutated AML in Real-World Setting

12/06/2020

Results from a real-world study confirm the effectiveness of first-line enasidenib therapy for patients with relapsed/refractory IDH2-mutated AML outside of the trial setting.

Results from a real-world study...

12/06/2020

Journal of Clinical Pathways

$Adding Daratumumab to Pomalidomide and Dexamethasone Improves PFS in Relapsed/Refractory MM$

Videos

Adding Daratumumab to Pomalidomide and Dexamethasone Improves PFS in Relapsed/Refractory MM

12/04/2020

Journal of Clinical Pathways

Conference Coverage

2015 American Society of Hematology Annual Meeting & Exposition

02/16/2016

JCP Editors

In April of 1958, the American Society of Hematology (ASH) was formed in Atlantic City, NJ, when 300 hematologists gathered to share their insights regarding blood diseases. Today, ASH is one of the world’s largest...

In...

02/16/2016

Journal of Clinical Pathways